Skip to content

Bioalmanac

PNC-27

p53-derived peptide · PNC27

Preclinical

Status reviewed 18 Aug 2026

A peptide designed to punch holes in cancer cell membranes. Sold to people who are frightened — on cell-culture evidence — with no human trial of any kind.

Storage

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C. Do not freeze once mixed.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Reconstitution — 10 mg vial, 2000 mcg dose

On a 1 mL U-100 syringe. Check every figure against your own vial before drawing.

Water addedConcentrationVolume to drawUnitsDoses per vial
1 mL10 mg/mL0.2 mL20 units5
2 mL5 mg/mL0.4 mL40 units5
3 mL3.333 mg/mL0.6 mL60 units5
5 mL2 mg/mL1 mL100 units5

Dose ranges reported in sources

Descriptions of what sources report, not recommendations.

GoalRangeFrequencySource
Commonly described community protocol1000–5000 mcgDaily, in coursesCommunity practice

When to stop

  • Any acute reaction: fever, breathlessness, chest pain, collapse. Seek emergency care.
  • Dark urine, reduced urine output, or confusion.
  • Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
  • Any deterioration in a diagnosed condition. Tell your oncology team what you have taken.

Not approved anywhere, and never studied in a human trial for any indication. Sold as a research chemical. Marketing it as a cancer treatment is not supported by any human evidence.

Arithmetic on values you enter. Not medical advice. Not reviewed by a clinician. · bioalmanac.com/peptides/pnc-27

Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.